Letters

Giving thyroid hormones to clinically hypothyroid but biochemically euthyroid patients

BMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7111.813 (Published 27 September 1997) Cite this as: BMJ 1997;315:813

Supporting authors' views would be unwise

  1. G J Beckett, Senior lecturer, university department of clinical biochemistrya,
  2. A D Toft, President, British Thyroid Associationa
  1. a a Royal Infirmary NHS Trust, Edinburgh EH3 9YW
  2. b University Clinical Departments at Aintree, Fazakerley Hospital, Liverpool L9 7AL
  3. c ME Association, Stanford le Hope, Essex SS17 0HA

    Editor—Gordon R B Skinner and colleagues advocated that a diagnosis of hypothyroidism in patients with suggestive symptoms should not be excluded on the basis of “normal” hormone concentrations.1 Furthermore, they proposed that an incremental trial of thyroxine for three months is not unreasonable in these patients.

    The consensus is that patients with subclinical hypothyroidism in whom serum thyroid stimulating hormone concentrations are consistently above the usually quoted upper limit of the reference range of 5 mU/l should be treated with thyroxine; this is particularly so if the patients have antibodies to thyroid peroxidase, a history of treatment of thyrotoxicosis, or a goitre.2 Two double blind trials in patients with subclinical hypothyroidism have shown that, after treatment with thyroxine, target organ function may improve and there may be a greater sense of wellbeing in some patients, though by no means all.3 The most cogent reason for treatment, however, is the knowledge that a considerable proportion of patients will develop overt hypothyroidism in future years,4 and it makes sense for the disorder to be “nipped in …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe